

Reference:	FOI.9809.22
Subject:	systemic anti-cancer therapies
Date of Request:	7 September 2022

Requested:

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions?

- Cervical cancer
- Endometrial cancer

In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?

2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:

- Paclitaxel in combination with Platinum and/or Bevacizumab
- Pembrolizumab in combination with Platinum and/or Bevacizumab
- Platinum standalone or in combination with Bevacizumab
- Toptecan in combination with Platinum and/or Bevacizumab
- Any other SACT

3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:

- Dostarlimab
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab in combination with Lenvatinib
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT

4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:

- Hormone therapy (Progesterone or Letrozole)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT

5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.

6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the number of patients who received hormone therapy as part of their SACT, or the number of patients who received the named treatments as first line treatment for endometrial cancer, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of

Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the number of patients who received hormone therapy, the UHB would be required to undertake a cross referencing exercise between the pharmaceutical systems and the patient records, to identify those who received hormone therapy treatment as part of their SACT not as treatment for another condition, as the information is not held centrally. Additionally, to identify the first line treatments requested under question 4, the UHB would need to undertake a manual trawl of patient records, as the information is not held centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

However, under section 16 of the FOIA, the UHB has an obligation to provide further advice and assistance and has therefore answered the remainder of your questions below.

1. The UHB does provide SACT treatments for endometrial cancer.
2. No patients were treated with the listed treatments for cervical cancer within the last six (6) months.
3. The table below provides the number of patients treated with the named treatments for endometrial cancer during the requested timeframe.

Treatment	Patients
Dostarlimab	0
Hormone therapy (Progesterone or Letrozole)	S.12 applied
Pembrolizumab in combination with Lenvatinib	0
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	15
Any other SACT	3

4. Section 12 exemption applied.
5. The UHB does not participate in any clinical trials for the treatment of cervical cancer.
6. The UHB does not participate in any clinical trials for the treatment of endometrial cancer.